Cohance Lifesciences Limited
3,039words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
INR 231
ntinue to show an encouraging trajectory driven by strong Pharma CDMO performance • Q2 Revenues at INR 231 Cr. (vs INR 278 Cr. last year), adjusted EBITDA (44% of rev) at INR 102 Cr (vs INR 103 Cr. last year
INR 278
n encouraging trajectory driven by strong Pharma CDMO performance • Q2 Revenues at INR 231 Cr. (vs INR 278 Cr. last year), adjusted EBITDA (44% of rev) at INR 102 Cr (vs INR 103 Cr. last year) and Adjusted P
44%
Pharma CDMO performance • Q2 Revenues at INR 231 Cr. (vs INR 278 Cr. last year), adjusted EBITDA (44% of rev) at INR 102 Cr (vs INR 103 Cr. last year) and Adjusted PAT at INR 80 Cr. Vs (INR 72 Cr. last
INR 102
rformance • Q2 Revenues at INR 231 Cr. (vs INR 278 Cr. last year), adjusted EBITDA (44% of rev) at INR 102 Cr (vs INR 103 Cr. last year) and Adjusted PAT at INR 80 Cr. Vs (INR 72 Cr. last year) • Revenue e
INR 103
Revenues at INR 231 Cr. (vs INR 278 Cr. last year), adjusted EBITDA (44% of rev) at INR 102 Cr (vs INR 103 Cr. last year) and Adjusted PAT at INR 80 Cr. Vs (INR 72 Cr. last year) • Revenue ex-AgChem and ex
INR 80
st year), adjusted EBITDA (44% of rev) at INR 102 Cr (vs INR 103 Cr. last year) and Adjusted PAT at INR 80 Cr. Vs (INR 72 Cr. last year) • Revenue ex-AgChem and ex-COVID molecule grew by 42% in H1 YoY Pg.
INR 72
ted EBITDA (44% of rev) at INR 102 Cr (vs INR 103 Cr. last year) and Adjusted PAT at INR 80 Cr. Vs (INR 72 Cr. last year) • Revenue ex-AgChem and ex-COVID molecule grew by 42% in H1 YoY Pg. 3 Table of Co
42%
ted PAT at INR 80 Cr. Vs (INR 72 Cr. last year) • Revenue ex-AgChem and ex-COVID molecule grew by 42% in H1 YoY Pg. 3 Table of Contents Pharma CDMO Sector Overview Specialty Chem CDMO Sector Over
7%
cule CMC Source: Industry Research Global CDMO Industry: Small Molecule CDMO Expected Growth of ~7% driven by Macro Tailwinds A Small Molecule Pipeline continues to grow despite growth in Biologic
35%
5 0 0 2 7 0 0 2 9 0 0 2 1 1 0 2 3 1 0 2 5 1 0 2 7 1 0 2 9 1 0 2 1 2 0 2 … D T Y 3 2 0 2 35% 29% 65% 71% 21% 79% 37% 28% 41% 63% 72% 59% 2017 2018 2019 2020 2021 2022 Small M
29%
0 2 7 0 0 2 9 0 0 2 1 1 0 2 3 1 0 2 5 1 0 2 7 1 0 2 9 1 0 2 1 2 0 2 … D T Y 3 2 0 2 35% 29% 65% 71% 21% 79% 37% 28% 41% 63% 72% 59% 2017 2018 2019 2020 2021 2022 Small Molecu
65%
7 0 0 2 9 0 0 2 1 1 0 2 3 1 0 2 5 1 0 2 7 1 0 2 9 1 0 2 1 2 0 2 … D T Y 3 2 0 2 35% 29% 65% 71% 21% 79% 37% 28% 41% 63% 72% 59% 2017 2018 2019 2020 2021 2022 Small Molecules
Advertisement